## Gaelle Quereux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3228166/publications.pdf

Version: 2024-02-01

516710 395702 1,141 36 16 33 citations g-index h-index papers 39 39 39 1571 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study. Journal of the American Academy of Dermatology, 2022, 86, 494-497.	1.2	18
2	Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study. Cancers, 2022, 14, 1659.	3.7	7
3	Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients. Medicine (United States), 2020, 99, e21329.	1.0	17
4	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. JAMA Dermatology, 2020, 156, 545.	4.1	40
5	Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. Journal of Investigative Dermatology, 2019, 139, 835-841.	0.7	69
6	Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases. Journal of the American Academy of Dermatology, 2019, 80, 558-562.	1.2	13
7	Incidence and Mortality of Pemphigus in France. Journal of Investigative Dermatology, 2019, 139, 469-473.	0.7	30
8	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. Journal of Investigative Dermatology, 2019, 139, 31-37.	0.7	55
9	A comparison of posttraumatic growth changes in breast cancer and melanoma Health Psychology, 2019, 38, 878-887.	1.6	12
10	Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. European Journal of Dermatology, 2019, 29, 315-321.	0.6	14
11	Efficacy and tolerance of photodynamic therapy for vulvar Paget's disease: a multicentric retrospective study. European Journal of Dermatology, 2018, 28, 351-355.	0.6	21
12	Use of Smartphones for Early Detection of Melanoma: Systematic Review. Journal of Medical Internet Research, 2018, 20, e135.	4.3	84
13	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet, The, 2017, 389, 2031-2040.	13.7	438
14	Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. BMC Research Notes, 2017, 10, 320.	1.4	7
15	5-fluorouracil chemowraps for the treatment of multiple actinic keratoses. European Journal of Dermatology, 2017, 27, 635-640.	0.6	6
16	Exceptional Association of Syringotropic Mycosis Fungoides with Chronic Lymphocytic Leukaemia. Acta Dermato-Venereologica, 2016, 96, 263-264.	1.3	1
17	Spectacular response of metastatic vulval Crohn's disease to infliximab treatment. International Journal of Dermatology, 2016, 55, 1146-1148.	1.0	3
18	Dramatic response of an inoperable Merkel cell carcinoma with imatinib. JAAD Case Reports, 2016, 2, 16-18.	0.8	4

#	Article	IF	CITATIONS
19	Sexual well-being in patients with vulvar disease: results from a preliminary prospective matched case–control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 194, 106-110.	1.1	8
20	Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. BMJ Open, 2015, 5, e007471.	1.9	12
21	Patients at elevated risk of melanoma: Individual predictors of non-compliance to GP referral for a dermatologist consultation. Preventive Medicine, 2014, 64, 48-53.	3.4	11
22	BRAF mutation in circulating DNA of melanoma patients at baseline and intertumor heterogeneity Journal of Clinical Oncology, 2014, 32, 9017-9017.	1.6	0
23	Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency Journal of Clinical Oncology, 2014, 32, 9069-9069.	1.6	0
24	Incidence and characteristics of melanoma brain metastases appearing during vemurafenib treatment Journal of Clinical Oncology, 2014, 32, 9042-9042.	1.6	0
25	Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opinion on Pharmacotherapy, 2013, 14, 1711-1721.	1.8	22
26	Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. Journal of the American Academy of Dermatology, 2013, 69, 890-897.	1,2	43
27	Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. European Journal of Dermatology, 2013, 23, 879-881.	0.6	40
28	Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. European Journal of Cancer Prevention, 2012, 21, 588-595.	1.3	30
29	Fotemustine for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2011, 12, 2891-2904.	1.8	24
30	Systemic Rituximab in Multifocal Primary Cutaneous Follicle Centre Lymphoma. Acta Dermato-Venereologica, 2011, 91, 562-567.	1.3	12
31	Development of an individual score for melanoma risk. European Journal of Cancer Prevention, 2011, 20, 217-224.	1.3	30
32	Creation and test of a questionnaire for self-assessment of melanoma risk factors. European Journal of Cancer Prevention, 2010, 19, 48-54.	1.3	16
33	Sudden Onset of an Aggressive Cutaneous Lymphoma in a Young Patient With Psoriasis: Role of Immunosuppressants. Acta Dermato-Venereologica, 2010, 90, 616-620.	1.3	18
34	Evaluation of the role of human herpes virus 6 and 8 in parapsoriasis. Experimental Dermatology, 2009, 18, 357-361.	2.9	3
35	Prospective trial on a school-based skin cancer prevention project. European Journal of Cancer Prevention, 2009, 18, 133-144.	1.3	18
36	Routine bone marrow biopsy inÂtheÂinitial evaluation ofÂprimary cutaneous B-cell lymphoma does not appear justified. European Journal of Dermatology, 2009, 19, 216-220.	0.6	15